
    
      Objectives: To analyze the effectiveness of Tocilizumab in moderate to severe Covid-19
      participants on the basis of predefined assessment criteria.

      Study Settings: Single center, Fatima Memorial Hospital, Lahore.

      Study Design: Quasi experimental.

      Duration of Study: From 12th May, 2020 to 12th July, 2020.

      Participants & Methods: Sample size and technique: Sample size was 93; 33 participants were
      kept in experimental group, given Tocilizumab, 8mg/kg intravenously or 162 mg subcutaneously
      and rest of the 60 participants were given corticosteroids, methylprednisolone 80 mg/day.
      Consecutive sampling.

      Failure of therapy was labeled when participants were intubated or died, and the endpoints
      were failure-free survival which was the primary endpoint and overall survival secondary at
      the time of discharge.
    
  